- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
AtriCure Inc(ATRC)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ATRC
11/20/2026: ATRC (2-star) is a SELL. SELL for 4 days. Simulated Profits (-7.22%). Updated daily EoD!
AtriCure is a medical technology company specializing in surgical devices for atrial fibrillation treatment and stroke reduction. Its main business strengths include a leading position in left atrial appendage management with the AtriClip franchise and strong surgeon adoption of its ablation clamps. The primary growth opportunity lies in expanding hybrid therapies and international markets, balanced against risks from intense med-tech competition and hospital budget sensitivity. The stock suits growth-oriented investors willing to monitor ongoing commercial execution and clinical trial progress.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | AtriCure delivers consistent double-digit revenue expansion fueled by innovative medical device adoption in underpenetrated markets. |
| Momentum investor | Strong fit while signal remains positive | The stock frequently attracts institutional momentum during periods of strong quarterly earnings beats and positive clinical trial readouts. |
| Value investor | Weak fit | The company trades at a premium valuation reflecting its growth profile rather than near-term earnings or book value metrics. |
| Dividend investor | Weak fit | AtriCure does not pay dividends, retaining all earnings to fund research and commercial expansion. |
| Low-risk investor | Mixed fit | As a mid-cap medical technology growth stock, it experiences higher volatility and regulatory exposure than large-cap healthcare stalwarts. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium / high | Growth-oriented medical technology stocks often experience sharp price swings based on market sentiment and earnings execution. |
| Valuation risk | Medium / high | Higher valuation multiples leave the stock susceptible to corrections if revenue growth slows or profitability targets are delayed. |
| Competition risk (Medtronic and Abbott) | High | Well-capitalized medical device competitors can bundle products or aggressively contest market share in surgical ablation. |
| Business quality | Strong | Proprietary technology, sticky surgeon relationships, and strong gross margins underpin a high-quality medical franchise. |
| Dividend income | Low / none | Income-focused investors receive no cash return from dividends. |
| Execution risk | Medium | Successful scaling depends heavily on clinical education, sales force productivity, and flawless regulatory compliance. |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.82B USD | Price to earnings Ratio 178.68 | 1Y Target Price 64.89 |
Price to earnings Ratio 178.68 | 1Y Target Price 64.89 | ||
Volume (30-day avg) 750.2K shares | Beta 1.21 | 52 Weeks Range 25.36 - 66.02 | Updated Date 11/20/2026 |
52 Weeks Range 25.36 - 66.02 | Updated Date 11/20/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.31 |
Sector & Industry Intelligence
Sector
Healthcare
Constructive- Sentiment
- Strong Bullish
- Momentum
- BUY Breadth Improving
- BUY participation
- 55.2%
- Active BUY / eligible
- 53 / 96
- 30-Day BUY Count Change
- +19
- Market state
- Strong Bullish
More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.
Industry
Medical Instruments & Supplies
- BUY participation
- 50.0%
- Active BUY / eligible
- 1 / 2
- 30-Day BUY Count Change
- +1
Eligible universe: 2 stocks.
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.

Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit -24.26% | Avg. Invested days 28 | Today’s Advisory SELL |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Surgical Ablation Disposables and Systems | Sale of single-use clamps, pens, and multi-use radiofrequency and cryoablation generators to hospitals. | This is the core recurring revenue stream generated each time a surgeon performs a cardiac ablation procedure. |
| Left Atrial Appendage Management (AtriClip) | Sales of specialized AtriClip exclusion devices designed to mitigate stroke risks. | A high-margin, rapidly growing product line that serves as a primary commercial growth engine. |
| International Markets | Direct and distributor-led sales across Europe, Asia, and other global healthcare territories. | Provides geographic diversification and a long-term runway for international market penetration. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-11-03 | When After Market | Estimate 0.01 | Actual 0.17 |
Profitability
Profit Margin 2.52% | Operating Margin (TTM) 2.89% |
Management Effectiveness
Return on Assets (TTM) 1.57% | Return on Equity (TTM) 2.95% |
Valuation
Trailing PE 178.68 | Forward PE 212.77 | Enterprise Value 2.66B | Price to Sales(TTM) 4.78 |
Enterprise Value 2.66B | Price to Sales(TTM) 4.78 | ||
Enterprise Value to Revenue 4.51 | Enterprise Value to EBITDA 61.61 | Shares Outstanding 50.92M | Shares Floating 48.88M |
Shares Outstanding 50.92M | Shares Floating 48.88M | ||
Percent Insiders 3.73 | Percent Institutions 112.29 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

